Skip to main content
    Q

    Qiagen NV (QGEN)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE

    $46.18
    +0.62 (+1.36%)

    Market Cap: $9.38B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    95%(37/39)
    Avg Surprise
    +5.87%
    Streak
    6 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$0.62
    Range$0.61 - $0.64
    9 analysts
    EPS RevisionsNo revisions (7d)
    0
    5
    30d
    EPS Estimate DriftChange to current
    90d ago$0.63-1.9%
    60d ago$0.62+0.3%
    30d ago$0.62+0.3%
    7d ago$0.62-0.1%
    Current$0.62
    Revenue Consensus
    $536M
    Range$531M - $538M
    9 analysts
    Period ending Dec 31, 2026
    EPS Consensus$0.67
    Range$0.66 - $0.69
    13 analysts
    Revenue Consensus
    $573M
    Range$559M - $586M
    17 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.67---
    Sep 26EST
    		-$0.62---
    Jun 26
    Reported Aug 5
    		$0.62$0.60+3.33%Beat-1.6%
    Mar 26
    Reported May 6
    		$0.54$0.54+0.00%Beat-6.9%
    Dec 25
    Reported Feb 4
    		$0.62$0.62+0.00%Beat-3.1%
    Sep 25
    Reported Nov 4
    		$0.64$0.62+3.23%Beat+3.2%
    Jun 25
    Reported Aug 5
    		$0.63$0.63+0.00%Beat+5.0%
    Mar 25
    Reported May 7
    		$0.58$0.54+7.41%Beat+16.0%
    Dec 24
    Reported Feb 5
    		$0.64$0.65-1.54%Miss+6.7%
    Sep 24
    Reported Nov 6
    		$0.62$0.59+5.08%Beat+10.7%
    Jun 24
    Reported Jul 31
    		$0.60$0.56+7.14%Beat+5.3%
    Mar 24
    Reported Apr 29
    		$0.50$0.47+6.38%Beat-12.3%
    Dec 23
    Reported Feb 6
    		$0.60$0.60+0.00%Beat+1.7%
    Sep 23
    Reported Oct 30
    		$0.56$0.54+3.70%Beat-5.1%
    Jun 23
    Reported Aug 8
    		$0.57$0.56+1.79%Beat+0.0%
    Mar 23
    Reported May 3
    		$0.57$0.51+11.76%Beat-36.0%
    Dec 22
    Reported Feb 7
    		$0.59$0.52+13.46%Beat-28.9%
    Sep 22
    Reported Nov 7
    		$0.59$0.51+15.69%Beat-9.2%
    Jun 22
    Reported Jul 26
    		$0.57$0.51+11.76%Beat-24.0%
    Mar 22
    Reported Apr 26
    		$0.89$0.80+11.25%Beat+20.3%
    Dec 21
    Reported Feb 8
    		$0.83$0.68+22.06%Beat+9.2%
    Sep 21
    Reported Nov 3
    		$0.65$0.60+8.33%Beat+0.0%
    Jun 21
    Reported Jul 29
    		$0.75$0.74+1.35%Beat+23.0%
    Mar 21
    Reported May 3
    		$0.74$0.70+5.71%Beat+94.7%
    Dec 20
    Reported Feb 9
    		$0.76$0.71+7.04%Beat+40.7%
    Sep 20
    Reported Oct 27
    		$0.65$0.62+4.84%Beat+62.5%
    Jun 20
    Reported Aug 4
    		$0.61$0.54+12.96%Beat+64.9%
    Mar 20
    Reported May 6
    		$0.38$0.30+26.67%Beat+26.7%
    Dec 19
    Reported Feb 4
    		$0.54$0.49+10.20%Beat+20.0%
    Sep 19
    Reported Oct 30
    		$0.40$0.39+2.56%Beat+2.6%
    Jun 19
    Reported Jul 24
    		$0.37$0.37+0.00%Beat+0.0%
    Mar 19
    Reported May 6
    		$0.30$0.29+3.45%Beat+3.4%
    Dec 18
    Reported Feb 4
    		$0.45$0.44+2.27%Beat-6.2%
    Sep 18
    Reported Oct 29
    		$0.39$0.37+5.41%Beat+8.3%
    Jun 18
    Reported Jul 31
    		$0.37$0.36+2.78%Beat+12.1%
    Mar 18
    Reported May 2
    		$0.29$0.27+7.41%Beat+31.8%
    Dec 17
    Reported Jan 31
    		$0.48$0.46+4.35%Beat+9.1%
    Sep 17
    Reported Nov 6
    		$0.36$0.36+0.00%Beat-
    Jun 17
    Reported Jul 27
    		$0.33$0.32+3.13%Beat-
    Mar 17
    Reported May 2
    		$0.22$0.23-4.35%Miss-
    Dec 16
    Reported Feb 1
    		$0.44$0.43+2.33%Beat-

    Dividends

    Dividend Metrics

    Forward Yield0.76%
    Forward Annual Dividend$0.35
    Payout Ratio17.77%
    FrequencyAnnual
    Pay MonthsJan, Jul

    Key Metrics

    Valuation
    P/E Ratio19.08EV/EBITDA14.89x
    Price/FCF21.44xFCF Yield4.66%
    Profitability
    Profit Margin19.50%Operating Margin26.30%
    ROE11.90%ROIC8.88%
    Financial Health
    Debt/Equity0.49xInterest Coverage12.71x
    Current Ratio2.85xQuick Ratio2.31x
    Trading Statistics
    Beta0.61Avg Volume2.17M
    52-Week High$57.3052-Week Low$32.24

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$45.34
    SMA 20$44.64
    SMA 50$43.72
    SMA 200$42.28
    EMA 10$45.24
    EMA 20$44.72
    EMA 50$43.57
    EMA 200$42.47

    MACD

    Line: 0.65Signal: 0.55Hist: 0.10

    ADX

    ADX: 12.9+DI: 28.6-DI: 19.3

    Aroon & PSAR

    Aroon Up72.0
    Aroon Down8.0
    PSAR$43.97

    Bollinger Bands

    Upper Band$46.63
    Lower Band$42.66
    %B Position889%(Upper)
    Band Width0.89

    RSI (14-Day)

    Neutral
    60.0

    Momentum Oscillators

    Stoch %K70.9
    Stoch %D66.9
    Williams %R-20.6
    ROC (10d)9.8%
    Momentum4.14
    CCI (20d)126.2
    MFI (14d)60.7

    Volatility Measures

    ATR (14d)$1.25(2.7%)
    StdDev (20d)0.99
    Hist Vol37.5%(Moderate)

    Volume Flow

    VWAP$46.09
    OBV-18.0M
    AD Line-70.0M
    CMF (20d)-0.064

    Volume Metrics

    Avg Vol (20d)2.2M
    Vol Ratio0.6x
    VWMA (20d)$44.59

    Pivot Points

    R3$47.03
    R2$46.70
    R1$46.13
    Pivot Point$45.80
    S1$45.23
    S2$44.90
    S3$44.33

    Advanced Oscillators

    TSI12.27
    Ultimate Osc47.4
    KST43.12

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$535.04M$492.32M$540.42M$532.58M$533.54M$483.46M$521.20M$501.87M$496.35M$458.80M$509.16M$475.89M
    Cost of Revenue$194.65M$182.72M$223.15M$201.32M$199.25M$174.78M$187.91M$193.56M$461.58M$167.81M$193.06M$177.93M
    Gross Profit$340.39M$309.60M$317.27M$331.26M$334.29M$308.68M$333.29M$308.31M$34.76M$290.99M$316.10M$297.96M
    Operating Expenses$207.99M$192.98M$163.37M$202.10M$212.38M$193.33M$214.19M$196.20M$263.20M$196.04M$205.49M$200.78M
    R&D$50.43M$48.26M$47.23M$48.75M$47.75M$43.78M$48.60M$44.45M$49.10M$51.33M$45.97M$47.93M
    SG&A$30.09M$27.78M$33.13M$30.29M$30.65M$31.61M$27.85M$29.39M$28.62M$27.57M$28.47M$28.65M
    Operating Income$132.40M$116.63M$153.90M$129.16M$121.90M$115.35M$119.10M$112.10M$-228,437,000$94.95M$110.61M$97.18M
    Interest Income$9.36M$10.56M$20.00M$15.07M$13.86M$15.39M$15.09M$18.25M$16.91M$17.76M$19.26M$20.38M
    Interest Expense$10.02M$11.05M$10.14M$8.22M$7.61M$7.29M$11.14M$11.48M$10.92M$10.29M$12.44M$13.02M
    Income Before Tax$132.10M$85.83M$109.17M$134.73M$126.82M$119.55M$125.85M$116.46M$-223,451,000$102.29M$118.88M$99.83M
    Income Tax Expense$28.70M$17.79M$1.34M$4.68M$30.57M$28.79M$37.53M$18.40M$-39,991,000$21.62M$21.21M$22.01M
    Net Income$103.40M$68.04M$107.83M$130.04M$96.25M$90.76M$88.32M$98.06M$-183,460,000$80.67M$97.66M$77.82M
    EBITDA$192.68M$148.09M$168.70M$193.91M$183.90M$170.75M$182.55M$177.93M$-159,136,000$166.91M$182.89M$163.42M
    EBIT$142.13M$96.88M$119.31M$142.94M$134.43M$126.84M$137.00M$127.94M$-212,529,000$112.58M$131.32M$112.85M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about QGEN

    Government Contracts

    Gov Obligations (TTM)
    $4.78M
    Gov Obligations / Revenue
    0.2%
    Obligations YoY
    -30.0%
    Active Awards
    105
    New Awards (TTM)
    64
    Avg Remaining Term
    6.2 mo

    Top agency: Department of Veterans Affairs at 31.5% of trailing twelve month obligations across 8 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C26226N0230Department of Veterans AffairsDepartment of Veterans Affairs$835369Dec 9, 2025
    W9124926PA005Department of DefenseDepartment of the Army$267622Jan 1, 2026
    15F06726F0000329Department of JusticeFederal Bureau of Investigation$245000Mar 5, 2026
    75N96026P00005Department of Health and Human ServicesNational Institutes of Health$220150Jan 1, 2026
    36C26226P0924Department of Veterans AffairsDepartment of Veterans Affairs$161777Jun 27, 2026
    75F40126F19008Department of Health and Human ServicesFood and Drug Administration$137961Jun 1, 2026
    75N90026P00032Department of Health and Human ServicesNational Institutes of Health$114304Dec 23, 2025
    HT942726FE045Department of DefenseDefense Health Agency$111631Apr 14, 2026
    36C25726N0059Department of Veterans AffairsDepartment of Veterans Affairs$106688Dec 1, 2025
    36C25526N0024Department of Veterans AffairsDepartment of Veterans Affairs$102515Oct 9, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    JPMorgan raises target for Qiagen stock to USD 55.00

    JPMorgan has increased its target price for Qiagen (QGEN) stock from USD 50.00 to USD 55.00, maintaining an overweight rating. This decision follows Qiagen's strong Q2 2026 revenue of USD 535.04 million...

    ad-hoc-news.de•10/16/26•Bullish

    JPMorgan raises Qiagen target from USD 50 to USD 55 for Qiagen stock

    JPMorgan has increased its price target for Qiagen stock from USD 50 to USD 55, maintaining an "Overweight" rating ahead of the company's Q3 results. Qiagen reported Q2 revenue of USD 535.04 million and adjusted EPS...

    ad-hoc-news.de•10/16/26•Bullish

    JPMorgan raises target to USD 55 for Qiagen stock

    JPMorgan has raised its price target for Qiagen stock from USD 50 to USD 55, maintaining an Overweight rating, following strong second-quarter revenue and earnings per share results. This new target is significantly...

    ad-hoc-news.de•10/15/26•Bullish

    Qiagen Is Maintained at Overweight by JP Morgan

    JP Morgan has reiterated its Overweight rating on Qiagen. This indicates a positive outlook on the company's stock performance from the financial institution.

    Moomoo•10/14/26•Bullish

    QIAGEN N.V. (QIA) BlackRock Files Voting Rights Notice With AFM

    QIAGEN N.V. (QIA) reported that the Dutch AFM has disclosed a notification from BlackRock, Inc. concerning its voting rights in QIAGEN, with a transaction date of October 9...

    TradingView•10/14/26•Neutral

    QGEN Valuation and Fair Value

    P/E
    19.1x
    Forward P/E
    13.5x
    EV/EBITDA
    14.9x
    P/FCF
    21.4x
    PEG
    1.2x
    P/B
    2.9x
    See GNG's fair value

    QGEN Profitability: Margins, ROIC and FCF

    Gross margin
    61.8%
    Operating margin
    26.3%
    Net margin
    19.5%
    ROIC
    8.9%
    ROE
    11.9%
    FCF margin
    21.3%
    FCF yield
    4.7%

    QGEN Competitors

    CompanyTicker
    10X Genomics IncTXG
    Insulet CorporationPODD
    Henry Schein IncHSIC
    Protagonist Therapeutics IncPTGX
    Krystal Biotech IncKRYS
    Cytokinetics IncCYTK
    Bio-Rad Laboratories IncBIO
    Kymera Therapeutics IncKYMR

    Sector: Healthcare

    QGEN Analyst Ratings

    Consensus
    Buy
    Analysts
    16
    Strong Buy
    4
    Buy
    4
    Hold
    8
    Sell
    0
    Strong Sell
    0

    QGEN Bull Case vs Bear Case

    Bull case

    • QGEN converts 21.3% of revenue into free cash flow.

    QGEN Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    2.2%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $0.62
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 5 down

    QGEN Dividend

    Forward yield
    0.8%
    Payout ratio
    17.8%
    Pay months
    Jan, Jul

    Frequently Asked Questions About QGEN

    What is QGEN's current dividend yield?

    Qiagen NV (QGEN) has a forward dividend yield of 0.76%.

    Does QGEN pay dividends?

    Yes, Qiagen NV pays dividends with a forward dividend yield of 0.76%.

    What is QGEN's P/E ratio?

    Qiagen NV has a price-to-earnings (P/E) ratio of 19.08.

    What is QGEN's market cap?

    Qiagen NV (QGEN) has a market capitalization of $9.38B with a current stock price of $46.18.

    Related stocks

    Sector: Healthcare

    All stocks starting with Q

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In